


05-09-02

GP/1617
RECEIVED
MAY 13 2002
TECH CENTER 1600/2900



DOC# NO.: ADOL-0497

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Lawrence I. Kruse et al.

Serial No.: 09/769,450

Group Art Unit: 1617

Filing Date: January 26, 2001

Examiner: S. Wang

For: KAPPA AGONIST COMPOUNDS, PHARMACEUTICAL FORMULATIONS
AND METHOD OF PREVENTION AND TREATMENT OF PRURITIS
THEREWITH

EXPRESS MAIL LABEL NO: EL884784338US

DATE OF DEPOSIT: May 7, 2002

EL884784338US

Box ☒ NON-FEE

☐ AF

Assistant Commissioner for Patents
Washington DC 20231

Sir:

AMENDMENT TRANSMITTAL LETTER

Transmitted herewith for filing in the above-identified patent application is:

- ☐ A Preliminary Amendment.
- ☐ An Amendment Responsive to the Office Action Dated _____.
- ☐ An Amendment Supplemental to the Paper filed _____.
- ☒ Other: Reply Under 37 CFR 1.111 to Office Action Dated January 7, 2002.
- ☒ Applicant(s) has previously claimed small entity status under 37 CFR §1.27.
- ☐ Applicant(s) by its/their undersigned attorney, claims small entity status under 37



DOCKET NO.: ADOL-0497

- 2 -

TECH CENTER 1600/2900

RECEIVED
PATENT
MAY 13 2002

CFR §1.27 as:

- ☐ an Independent Inventor
- ☐ a Small Business Concern
- ☐ a Nonprofit Organization

- ☐ This application is no longer entitled to small entity status. It is requested that this be noted in the files of the Patent and Trademark Office.

- ☐ Substitute Pages _____ of the Specification are enclosed.

- ☐ An Abstract is enclosed.

- ☐ _____ Sheets of Proposed Corrected Drawings are enclosed.

- ☐ A Certified Copy of each of the following applications: _____
_____ is enclosed.

- ☐ An Associate Power of Attorney is enclosed.

- ☐ Information Disclosure Statement.
 - ☐ Attached Form 1449.
 - ☐ A copy of each reference as listed on the attached Form PTO-1449 is enclosed herewith.

- ☐ Appended Material as follows: _____

- ☐ Other Material as follows: _____



DOCKET NO.: ADOL-0497

- 3 -

FEE CALCULATION



No Additional Fee is Due.

RECEIVED
 MAY 13 2002
 TECH CENTER 1600/2900

				SMALL ENTITY		NOT SMALL ENTITY	
	REMAINING AFTER AMENDMENT	HIGHEST PAID FOR	EXTRA	RATE	FEE	RATE	FEE
TOTAL CLAIMS	9	20 (20 MINIMUM)	0	\$9 EACH	\$0.00	\$18 EACH	\$
INDEP. CLAIMS	2	3 (3 MINIMUM)	0	\$42 EACH	\$0.00	\$84 EACH	\$
FIRST PRESENTATION OF MULTIPLE DEPENDENT				\$140	\$	\$280	\$
<input type="checkbox"/> ONE MONTH EXTENSION OF TIME				\$55	\$	\$110	\$
<input type="checkbox"/> TWO MONTH EXTENSION OF TIME				\$200	\$	\$400	\$
<input type="checkbox"/> THREE MONTH EXTENSION OF TIME				\$460	\$	\$920	\$
<input type="checkbox"/> FOUR MONTH EXTENSION OF TIME				\$720	\$	\$1440	\$
<input type="checkbox"/> FIVE MONTH EXTENSION OF TIME				\$980	\$	\$1960	\$
<input type="checkbox"/> LESS ANY EXTENSION FEE ALREADY PAID				minus	(\$)	minus	(\$)
<input type="checkbox"/> TERMINAL DISCLAIMER				\$55	\$	\$110	\$
<input type="checkbox"/> OTHER FEE OR SURCHARGE AS FOLLOWS:							
TOTAL FEE DUE					\$0.00		\$



A Check is Enclosed in the Foregoing Amount Due.



Petition is hereby made under 37 C.F.R. 1.136(a) to extend the time for response to the Office Action of @@ to and through @@ comprising an extension of the shortened statutory period of @@ month(s).



The Commissioner is hereby requested to grant an extension of time for the appropriate length of time, should one be necessary, in connection with this filing or any future filing submitted to the U.S. Patent and Trademark Office in the above-identified application during the pendency of this application. The Commissioner is further authorized to charge any fees related to any such extension of time to deposit



DOCKET NO.: ADOL-0497

- 4 -

account 23-3050. This sheet is provided in duplicate.

☒ The Commissioner is authorized to charge payment of the following fees and to refund any overpayment associated with this communication or during the pendency of this application to deposit account 23-3050. This sheet is provided in duplicate.

☐ The Foregoing Amount Due for Filing this Paper.

☒ Any additional filing fees required, including fees for the presentation of extra claims under 37 C.F.R. 1.16.

☒ Any additional patent application processing fees under 37 C.F.R. 1.17 or 1.20(d).

SHOULD ANY DEFICIENCIES APPEAR with respect to this application, including deficiencies in payment of fees, missing parts of the application or otherwise, the United States Patent and Trademark Office is respectfully requested to promptly notify the undersigned.

Date:

5/17/02



David A. Cherry
Registration No. 35,099

Woodcock Washburn LLP
One Liberty Place - 46th Floor
Philadelphia PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439

© 2001 WW

RECEIVED
MAY 13 2002
PATENT
TECH CENTER 1600/2000

DOCKET NO.: ADOL-0497



TECH CENTER 1600/2900

MAY 13 2002

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of:

Lawrence I. Kruse et al.

Serial No.: 09/769,450

Group Art Unit: 1617

Filed: January 26, 2001

Examiner: S. Wang

For: **KAPPA AGONIST COMPOUNDS, PHARMACEUTICAL
FORMULATIONS AND METHOD OF PREVENTION AND
TREATMENT OF PRURITIS THEREWITH**

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

**REPLY UNDER 37 C.F.R. § 1.111 TO
OFFICE ACTION DATED JANUARY 7, 2002**

In response to the Office Action mailed January 7, 2002, please amend the application, without prejudice, as follows.

In the Claims

25. (Amended) A method of treating or preventing pruritus in a mammal in need of such prevention or treatment, said method comprising administering to said mammal a non-peptide kappa opiate receptor agonist, or a pharmaceutically acceptable salt thereof, that is substantially devoid of central nervous system effects, in a pharmaceutically acceptable carrier.

Cancel Claims 26 and 33, without prejudice.